When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI:10.1016/j.beha.2022.101404

Anjali Advani

引用次数: 0

Abstract

The treatment of acute lymphoblastic leukemia (ALL) has changed significantly over the last decade. With the approval of novel antibody based therapies in the relapsed/refractory setting, many of these agents are starting to be used in the upfront setting in clinical trials for older patients. These results have been impressive, and further trials are underway. Other targeted therapies (i.e. BCL inhibitors) are being explored. This article will discuss the incorporation of novel agents to “replace” chemotherapy in induction.

查看原文本刊更多论文

成人急性淋巴细胞白血病(ALL)的前期诱导治疗何时可以替代化疗?

急性淋巴细胞白血病(ALL)的治疗在过去十年中发生了重大变化。随着新的基于抗体的治疗方法在复发/难治性环境中的批准，许多这些药物开始用于老年患者的临床试验的前期设置。这些结果令人印象深刻，进一步的试验正在进行中。其他靶向治疗(如BCL抑制剂)正在探索中。本文将讨论在诱导中加入新的药物来“替代”化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.